Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESOC 2024 | Results of the RICH-2 trial of remote ischemic conditioning in ICH

Wenbo Zhao, MD, PhD, Xuanwu Hospital, Capital Medical University, Beijing, China, shares the results of the RICH-2 trial, which randomized 458 patients with acute intracerebral hemorrhage (ICH) to receive remote ischemic conditioning (RIC) or sham RIC for seven days. The trial was based on evidence of accelerated hematoma absorption and improved neurological outcomes in animal models treated with RIC. The pilot RICH-1 trial demonstrated the safety of RIC in patients with ICH and suggested an association with improved hematoma resolution rate and perihematomal edema. In the RICH-2 randomized, Phase III trial, there was no difference in functional independence rates at 90 days between the two trial arms. Dr Zhao comments on possible explanations for these findings, including the mild severity of ICH in the trial. A subgroup analysis indicated that patients with a hematoma volume of 21-30ml favored RIC treatment. This interview took place at the 10th European Stroke Organisation Conference (ESOC) 2024 in Basel, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.